New safety alert over rosuvastatin
Concern is growing over the safety of lipid-lowering drug rosuvastatin (Crestor) after manufacturer AstraZeneca issuing its second warning to GPs in less than a month.
In a letter to all practices, it cautioned that the maximum 40mg dose should not be used in patients at risk of muscle side-effects.
Last month the company wrote to GPs warning them only to initiate treatment at the minimum 10mg dose following yellow card reports of non-fatal rhabdomyolysis in four patients (Pulse, May 24).
Now, following a Europe-wide review of safety information, it has said the 40mg dose should only be necessary for the minority of patients with severe hypercholesterolaemia at high cardiovascular risk.
Patients on the 40mg dose who have not seen a specialist should have the dose decreas-ed at their next appointment or get a specialist referral.